Compliance RiskGhg IntensityWater Intensity
Risk Breakdown
GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.0
EPR Exposure
5.0
Compliance Risk
10.0
HR Risk
3.0
Governance Risk
3.0
Financial Exposure
Est. Compliance Cost₹15–55 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated3,808.0 T
Governance
Anti-Corruption PolicyYes
Conflict of Interest PolicyYes
BRSR AssurancePartial
Assurance ProviderDNV Business Assurance India Private Limited
Double Materiality
Financial Materiality5.0
Impact Materiality4.6
QuadrantFinancially Material
Supply Chain
MSME Sourcing0.1%
Lifecycle AssessmentYes
Product ReclaimYes
Material Risks
e-waste
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Life Cycle Assessment | LCA conducted for products | Achieved |
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
Glenmark Pharmaceuticals Limited carries a medium ESG financial risk score of 5.0/10. Primary risk drivers are compliance risk, ghg intensity. Estimated annual compliance cost exposure: ₹15–55 crore.
Source: Glenmark Pharmaceuticals Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.